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2Abstract
Brain nitric oxide (NO) is mainly generated by 
neuronal NO synthase (NOS) and inducible NOS. In various 
cells, NO has been shown to regulate cyclooxygenase (COX),
which is divided into two isoforms, COX-1 and COX-2. We 
previously reported that bombesin injected into the right 
lateral ventricle evokes the secretion of noradrenaline 
and adrenaline from adrenal medulla by brain COX-mediated 
mechanisms in rats. In the present study, we examined 
whether NOS is involved and which types of NOS and COX are
involved in the bombesin-induced activation of central 
adrenomedullary outflow using urethane-anesthetized rats. 
Intracerebroventricularly (i.c.v.) administered bombesin 
(1 nmol/animal)-induced elevation of plasma noradrenaline 
and adrenaline was attenuated by pretreatment with N?-
nitro-L-arginine methyl ester (a non-selective NOS 
inhibitor) (0.37 and 1.11 ?mol/animal, i.c.v.). 7-
Nitroindazole (a neuronal NOS inhibitor) (0.03 and 0.12
?mol/animal, i.c.v.) attenuated the bombesin-induced 
elevation of plasma noradrenaline alone, while S-
ethylisothiourea (an inducible NOS inhibitor) (2.7 and 27
nmol/animal, i.c.v.) and cycloheximide (an inhibitor of 
protein synthesis) (0.1 and 0.2 ?mol/animal, i.c.v.) only 
attenuated the bombesin-induced elevation of plasma 
adrenaline. Furthermore, the bombesin-induced elevation of 
both catecholamines was attenuated by ketoprofen (a 
3selective COX-1 inhibitor) (1 and 2 ?mol/animal, i.c.v.), 
but not influenced by NS-398 (a selective COX-2 inhibitor)
(0.8 and 1.6 ?mol/animal, i.c.v.). These results suggest 
that the brain neuronal NOS/COX-1 and inducible NOS/COX-1
are respectively involved in the bombesin-induced 
secretion of noradrenaline and adrenaline from the adrenal 
medulla in rats.
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41.  Introduction
Nitric oxide (NO) has been recognized as a 
neurotransmitter or a neuromodulator in the central 
nervous system (Moncada et al., 1991; Pacher et al., 2007).
NO is generated from the amino acid L-arginine by NO 
synthase (NOS) (Palmer et al., 1988; Moncada et al., 1991; 
Jaffrey and Snyder, 1995). Brain NOS mainly consists of 
neuronal NOS and inducible NOS, although NOS has been 
divided into three isoforms: neuronal, endothelial and 
inducible NOS (Costa et al., 1996; Pacher et al., 2007). 
Constitutively expressed neuronal NOS is the most abundant 
isoform in the brain including the hypothalamus, 
especially the paraventricular nucleus (Vincent and Kimura, 
1992). Since the hypothalamic paraventricular nucleus has 
been recognized as a regulatory center of the sympatho-
adrenomedullary system (Swanson and Sawchenko, 1983;
Jansen et al., 1995; Kenney et al., 2003), NO may play a 
role in regulating the central sympatho-adrenomedullary 
outflow (Zhang et al., 1997; Stern, 2004). Inducible NOS 
is formed in response to various cytokines and endotoxin 
in various cells including neurons and glial cells in the 
brain (Galea et al., 1992; Romero et al., 1996; Rothwell 
et al., 1996; Heneka and Feinstein, 2001). We previously 
reported the involvement of the brain NOS in centrally 
5administered interleukin-1?- and corticotropin-releasing 
factor (CRF)-induced activation of the sympatho-
adrenomedullary outflow using N?-nitro-L-arginine methyl 
ester (L-NAME) (a non-selective NOS inhibitor) in rats 
(Murakami et al., 1996; Okada et al., 2003b).
Cyclooxygenase (COX) is divided into two isoforms, 
COX-1 and COX-2. COX-1 is constitutively expressed in the 
majority of tissues, while COX-2 is generally undetectable 
or present at low levels in the resting state but is 
induced by various stimuli such as inflammatory cytokines 
(Smith et al., 1996). However, COX-2 has also been shown 
to be constitutively expressed in some tissues including 
the brain (Breder et al., 1995; Hetu and Riendeau, 2005).
We have already reported the involvement of brain COX in 
the bombesin-, interleukin-1?- and CRF-induced activation 
of sympatho-adrenomedullary outflow using indomethacin (a 
non-selective COX inhibitor) in rats (Okuma et al., 1996; 
Murakami et al., 1996; Yokotani et al., 2001).
Centrally administrated bombesin has been shown to 
evoke the secretion of both noradrenaline and adrenaline
from the adrenal medulla by brain COX-mediated mechanisms 
in rats, since the peptide-induced responses were abolished 
by central pretreatment with indomethacin and bilateral 
adrenalectomy in rats (Okuma et al., 1996; Yokotani et al., 
2005). The adrenal secretion of both catecholamines was 
6also demonstrated in the centrally administered arginine-
vasopressin- and histamine-induced responses in rats (Okada 
et al., 2003a; Shimizu et al., 2006; Yamaguchi-Shima et al., 
2007). In the present study, therefore, we examined whether 
NOS is involved and which types of NOS and COX are involved 
in the bombesin-induced activation of central 
adrenomedullary outflow with regard to the isoforms of NOS 
and COX, using urethane-anesthetized rats.
72. Materials and methods
2.1. Experimental procedures
Male Wistar rats weighing about 350 g were maintained 
in an air-conditioned room at 22–24°C under a constant 
day–night rhythm for more than 2 weeks and given food 
(laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and 
water ad libitum. Under urethane anesthesia (1.0 g/kg, 
i.p.), the femoral vein was cannulated for infusion of 
saline (1.5 ml/h), and the femoral artery was cannulated 
for collecting blood samples. After these procedures, 
animals were placed in a stereotaxic apparatus, as 
explained in our previous papers (Yokotani et al., 1995; 
Shimizu et al., 2004). The skull was drilled for
administration of test substances into the right lateral 
ventricle using a stainless-steel cannula (0.3 mm outer 
diameter). The stereotaxic coordinates of the tip of the 
cannula were as follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, 
anterior from the bregma; L, lateral from the midline; V, 
below the surface of the brain), according to the rat 
brain atlas (Paxinos and Watson, 1986). Four hours were 
allowed to elapse before the start of each experiment with 
the application of blocking reagent or vehicle-1.
Bombesin dissolved in filtered saline was slowly 
administered intracerebroventricularly (i.c.v.) in a 
volume of 10 ?l/animal using a 25-?l Hamilton syringe. 7-
8Nitroindazole, ketoprofen, and N-[2-(cyclohexyloxy)-4-
nitrophenyl]-methanesulfonamide (NS-398) dissolved in 100% 
N,N-dimethylformamide (DMF) were i.c.v. administered in a 
volume of 3 ?l/animal using a 10-?l Hamilton syringe. L-
NAME, S-ethylisothiourea and cycloheximide dissolved in 
filtered saline were i.c.v. administered in a volume of 5 
?l/animal using a 10-?l Hamilton syringe. Where blocking 
reagents were used, bombesin was i.c.v. administered 30 
min after the application of L-NAME, S-ethylisothiourea,
7-nitroindazole, ketoprofen or NS-398, but 120 min after 
the application of cycloheximide due to its slightly 
elevating effect on the basal plasma levels of 
catecholamines. Each animal received only one dose of 
blocking reagents or vehicles. Correct placement of the 
cannula was confirmed at the end of each experiment by 
verifying that a blue dye, injected through the cannula, 
had spread throughout the entire ventricular system.
All experiments were conducted in compliance with the 
guiding principles for the care and use of laboratory 
animals approved by Kochi University.
2.2.  Measurement of plasma catecholamines
Blood samples (250 ?l) were collected through an 
arterial catheter and were preserved on ice during 
experiments. Plasma was prepared immediately after the 
final sampling. Catecholamines in the plasma were 
9extracted by the method of Anton and Sayre (1962) with a 
slight modification and were assayed electrochemically 
with high performance liquid chromatography (HPLC) 
(Shimizu et al., 2004). Briefly, after centrifugation, the 
plasma (100 ?l) was transferred to a centrifuge tube 
containing 30 mg of activated alumina, 2 ml of twice 
deionized water, 1 ml of 1.5 M Tris Buffer (pH 8.6) 
containing 0.1 M disodium EDTA and 1 ng of 3,4-
dihydroxybenzylamine as an internal standard. The tube was 
shaken for 10 min and the alumina was washed three times 
with 4 ml of ice-cold twice deionized water. Then, 
catecholamines adsorbed onto the alumina were eluted with 
300 ?l of 4% acetic acid containing 0.1 mM disodium EDTA. 
A pump (EP-300: Eicom, Kyoto, Japan), a sample injector 
(Model-231XL; Gilson, Villiers-le-Bel, France) and an 
electrochemical detector (ECD-300: Eicom) equipped with a 
graphite electrode were used with HPLC. Analytical 
conditions were as follows: detector, +450 mV potential 
against an Ag/AgCl reference electrode; column, Eicompack 
CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M 
NaH2PO4-Na2HPO4 buffer (pH 6.0) containing 50 mg/l disodium
EDTA, 0.75 g/l 1-octanesulfate sodium and 15% methanol at 
a flow of 0.18 ml/min; injection volume, 40 ?l. The amount 
of catecholamine in each sample was calculated using the 
peak height ratio relative to that of 3,4-
dihydroxybenzylamine. By this assay, coefficients of 
variation for intra- and inter-assay were 3.0% and 3.7%, 
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respectively, and 0.5 pg of noradrenaline and adrenaline 
was accurately determined.
2.3.  Treatment of data and statistics
The area under the curve (AUC) was used to compare the 
effects of several kinds of inhibitors on the bombesin-
induced elevation of plasma catecholamines. All values are 
expressed as the means±S.E.M. of the net changes above the 
respective basal values. The data were analyzed by 
repeated-measure analysis of variance (ANOVA), followed by 
post-hoc analysis with the Bonferroni method. P values 
less than 0.05 were taken to indicate statistical 
significance.
2.4. Compounds
The following drugs were used: synthetic bombesin 
(Peptide Institute, Osaka, Japan); cycloheximide (MP 
Biomedicals, Solon, OH, U.S.A.); L-NAME hydrochloride 
(Sigma Aldrich Fine Chemicals, St. Louis, MO, U.S.A.); S-
ethylisothiourea hydrobromide, 7-nitroindazole and NS-398
(Cayman Chemical, Ann Arbor, MI, U.S.A.); ketoprofen (Wako, 
Osaka, Japan). All other reagents were of the highest 
grade available (Nacalai Tesque, Kyoto, Japan).
11
3.  Results
3.1.  Effects of L-NAME, 7-nitroindazole and S-
ethylisothiourea on the centrally administered bombesin-
induced elevation of plasma catecholamines
Treatments with vehicle-1 (5 ?l saline/animal, i.c.v.) 
and vehicle-2 (10 ?l saline/animal, i.c.v.) followed by 
blood sampling six times over a 120-min period had no 
effect on the basal plasma levels of noradrenaline and 
adrenaline (Fig. 1). 
Since we previously reported that bombesin (0.1, 1 and 
10 nmol/animal, i.c.v.) elevated plasma levels of both 
catecholamines in a dose-dependent manner (Okuma et al., 
1996), we used the dose of 1 nmol/animal in the present 
experiment. The administered bombesin rapidly increased 
plasma levels of noradrenaline and adrenaline (adrenaline 
> noradrenaline) (Fig. 1). These responses reached a 
maximum 30 min after administration of bombesin and then 
declined to near basal levels. However, intravenous 
administration of bombesin (1 nmol/animal) had no effect 
on the plasma levels of both catecholamines (data not 
shown).
Pretreatment with L-NAME (a non-selective NOS 
inhibitor) [1.11 ?mol (300 ?g)/animal, i.c.v.] had no 
effect on the basal plasma levels of both catecholamines 
(Fig. 1). L-NAME effectively attenuated the bombesin-
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induced elevation of both catecholamines in a dose-
dependent way [0.37 and 1.11 ?mol (100 and 300 ?g)/animal,
i.c.v.] (Fig. 1).
Pretreatment with vehicle-1 (3 ?l DMF/animal, i.c.v.) 
or 7-nitroindazole (a neuronal NOS inhibitor) [0.12 ?mol
(20 ?g)/animal, i.c.v.] had no effect on the basal plasma 
levels of both catecholamines (Fig. 2). 7-Nitroindazole 
[0.03 and 0.12 ?mol (5 and 20 ?g)/animal, i.c.v.] 
effectively attenuated the bombesin-induced noradrenaline 
response, but had no effect on the adrenaline response 
induced by the peptide (Fig. 2).
Pretreatment with S-ethylisothiourea (an inducible NOS 
inhibitor) [27 nmol (5 ?g)/animal, i.c.v.] had no effect 
on the basal plasma levels of noradrenaline and adrenaline 
(Fig. 3). S-Ethylisothiourea had no effect on the 
bombesin-induced noradrenaline response, but effectively 
attenuated the bombesin-induced adrenaline response in a 
dose-dependent manner [2.7 and 27 nmol (0.5 and 5 
?g)/animal, i.c.v.] (Fig. 3).
3.2.  Effect of cycloheximide on the centrally 
administered bombesin-induced elevation of plasma 
catecholamines
Pretreatment with vehicle-1 (5 ?l saline/animal, 
i.c.v.) or cycloheximide [0.2 ?mol (60 ?g)/animal, i.c.v.]
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had slightly, but not significantly, elevating effect on 
the basal plasma levels of noradrenaline and adrenaline 
(Fig. 4). 
Cycloheximide [0.1 and 0.2 ?mol (30 and 60 ?g)/animal,
i.c.v.] had no effect on the bombesin-induced 
noradrenaline response, while the reagent attenuated the 
bombesin-induced adrenaline response at a high dose of 
cycloheximide (0.2 ?mol/animal, i.c.v) (Fig. 4).
3.3.  Effects of ketoprofen and NS-398 on the centrally 
administered bombesin-induced elevation of plasma 
catecholamines
Pretreatment with vehicle-1 (3 ?l DMF/animal, i.c.v), 
ketoprofen (a inhibitor of COX-1) [2 ?mol (500 ?g)/animal,
i.c.v.] or NS-398 (a selective inhibitor of COX-2) [1.6
?mol (500 ?g)/animal, i.c.v.] had no effect on the basal 
plasma levels of noradrenaline and adrenaline (Figs. 5 and 
6).
Ketoprofen [1 and 2 ?mol (250 and 500 ?g)/animal,
i.c.v.] attenuated the bombesin-induced elevation of both 
catecholamines (Fig. 5), while NS-398 [0.8 and 1.6 ?mol
(250 and 500 ?g)/animal, i.c.v.] left the bombesin-induced 
elevation of both catecholamines largely unaffected (Fig. 
6).
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4.  Discussion
In the present experiments, we examined whether brain 
NOS is involved in the centrally administered bombesin-
induced elevation of plasma noradrenaline and adrenaline 
using L-NAME, a non-selective NOS inhibitor (Gross et al., 
1990). L-NAME effectively attenuated the bombesin-induced 
elevation of both catecholamines, indicating the 
involvement of brain NOS in the bombesin-induced secretion 
of noradrenaline and adrenaline from the adrenal medulla in 
rats. Then, we examined which type of NOS is involved in 
the bombesin-induced responses using 7-nitroindazole and S-
ethylisothiourea.
7-Nitroindazole is a potent and selective inhibitor of 
neuronal NOS with a Ki value of 0.09 ?M in purified porcine 
brain (Mayer et al., 1994) and with a Ki value of 1.6 ?M in 
bovine brain (Wolff and Gribin, 1994). The reagent 
decreased NO production in the rat cerebellum and 
hippocampus (Babbedge et al., 1993; Bush and Pollack, 2001), 
and prevented neuronal NOS-derived NO-mediated brain damage 
after hypoxia in the developing brain of the chick embryo
(Giusti et al., 2008). We previously reported that the 
central pretreatment with 7-nitroindazole had no effect on 
the centrally administered interleukin-1?-induced release 
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of noradrenaline from sympathetic nerves in rats (Murakami 
et al., 2002). In the present experiment, however, 7-
nitroindazole effectively attenuated the bombesin–induced 
elevation of plasma noradrenaline, but not adrenaline, 
suggesting the involvement of brain neuronal NOS in the 
bombesin-induced secretion of noradrenaline from the 
adrenal medulla in rats.
S-Ethylisothiourea is a potent and selective inhibitor
of inducible NOS (Szabó et al., 1994; Southan et al., 
1995; Nakane et al., 1995). S-Ethylisothiourea potently 
inhibits inducible NOS activity with a Ki value of 14.7 nM 
for partially purified inducible NOS obtained from 
lipopolysaccharide- and interferon-?-treated RAW 264.7 
macrophages and with about 20-fold more selectivity for 
murine inducible NOS than rat neuronal NOS (Nakane et al., 
1995). The reagent also inhibits inducible NOS-derived NO-
mediated suppression of the enhancement of 
vasoconstriction in diabetic rats (Ishikawa et al., 2004). 
We previously reported that central pretreatment with S-
ethylisothiourea effectively attenuated the release of 
noradrenaline from sympathetic nerves induced by centrally 
administered interleukin-1? in rats (Murakami et al., 
2002). In the present experiment, the S-ethylisothiourea
effectively attenuated the bombesin–induced elevation of 
plasma adrenaline, but not noradrenaline. The result 
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suggests the involvement of brain inducible NOS in the
bombesin-induced secretion of adrenaline from the adrenal 
medulla in rats.
To further clarify the involvement of brain inducible 
NOS in the bombesin-induced adrenaline response, we used 
cycloheximide, an inhibitor of protein synthesis (Obrig et 
al., 1971). Cycloheximide inhibits serum albumin-induced 
inducible NOS expression in RAW 267.4 macrophages (Poteser
and Wakabayashi, 2004), and central pretreatment with this 
reagent effectively attenuated the release of 
noradrenaline from sympathetic nerves induced by centrally 
administered interleukin-1? in rats (Murakami et al., 
2002). In the present experiments, cycloheximide 
attenuated the bombesin-induced adrenaline response alone. 
The result further suggests the involvement of inducible 
NOS in the bombesin-induced secretion of adrenaline from 
the adrenal medulla in rats.
Since the central pretreatment with indomethacin (500 
?g/animal) effectively attenuated the bombesin (1 
nmol/animal)-induced elevation of plasma noradrenaline and 
adrenaline in rats (Okuma et al., 1996), we examined which 
type of COX isoform is involved in the bombesin-induced 
responses using ketoprofen and NS-398. Ketoprofen has IC50
values of 0.02 and 1.08 ?M for COX-1 and COX-2 in human 
whole blood (Brideau et al., 1996), while NS-398 has IC50
17
values of 75 and 1.77 ?M for human recombinant COX-1 and 
COX-2 (Barnett et al., 1994), indicating that ketoprofen 
and NS-398 are selective inhibitors for COX-1 and COX-2, 
respectively. Recently, we reported the involvement of 
brain COX-1 in the centrally administered histamine-
induced secretion of both catecholamines from the adrenal 
medulla using ketoprofen and NS-398 in rats (Shimizu et 
al., 2006). In the present experiments, central 
pretreatment with ketoprofen effectively attenuated the 
bombesin-induced elevation of plasma noradrenaline and
adrenaline, while NS-398 had no effect on the peptide-
induced responses. These results suggest the involvement 
of brain COX-1 in the bombesin-induced secretion of both 
catecholamines from the adrenal medulla in rats.
The biosynthesis of prostaglandins is regulated by NO 
in various cell types. This phenomenon was first reported 
by Salvemini and coworkers (1993) who showed that NO 
activated COX and enhanced prostaglandin synthesis in the 
mouse macrophage cell line RAW264.7. Since then, this 
observation was confirmed and extended by other 
investigators in various cellular systems and animal 
models (Mollace et al., 2005). NO interacts with the thiol 
groups of cysteine in COX, thereby directly activating COX 
(Kim et al., 2005; Upmacis et al., 2006). This 
modification of cysteine residues in proteins is called S-
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nitrosylation, which has been recognized as an important
biological reaction of NO for post-translational 
regulation (Hess et al., 2005). We previously reported 
that centrally administered 3-morpholinosydnonimine (an NO 
donor)-induced elevation of plasma noradrenaline and 
adrenaline was abolished by central pretreatment with 2-
(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl 3-
oxide (an NO scavenger) and indomethacin, suggesting that 
NO is upstream to COX activation in the centrally mediated 
elevation of plasma catecholamines (Murakami et al., 1998). 
The possible link between brain NOS and COX has also been 
reported in the centrally administered interleukin-1??-
induced elevation of plasma noradrenaline in rats, due to 
the inhibitory effect of L-NAME and indomethacin on the
cytokine-induced response (Murakami et al., 1996). The 
present results further suggest the functional linkage 
between brain NOS and COX in the bombesin-induced 
secretion of both catecholamines from the adrenal medulla 
in rats.
In summary, we demonstrated that the brain neuronal 
NOS/COX-1 and inducible NOS/COX-1 are respectively 
involved in the centrally administered bombesin-induced 
secretion of noradrenaline and adrenaline from the adrenal 
medulla in rats.
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Legends to figures
Fig. 1.  Effect of N?-nitro-L-arginine methyl ester (L-
NAME) (a non-selective NOS inhibitor) on the centrally 
administered bombesin-induced elevation of plasma 
catecholamines. L-NAME [0.37 and 1.11 ?mol (100 and 300 
?g)/animal] or vehicle-1 (5 ?l saline/animal) was 
intracerebroventricularly (i.c.v.) administered 30 min 
before the administration of bombesin (1 nmol/animal, 
i.c.v.) or vehicle-2 (10 ?l saline/animal, i.c.v.). (A) 
Increments of plasma catecholamines above the basal at 
each time point are expressed as pg/ml. Arrows indicate 
the administrations of L-NAME/vehicle-1 and 
bombesin/vehicle-2. (B) The area under the curve (AUC) of 
the bombesin-induced elevation of plasma catecholamines 
above the basal is expressed as pg/2 h. ??Noradrenaline
and ??adrenaline: increments of noradrenaline and 
adrenaline above the basal in (A) and (B). Each point 
represents the mean±S.E.M. *Significantly different 
(p<0.05) from the vehicle-1- and bombesin-treated group. 
The actual values for noradrenaline and adrenaline at 0 
min were 117±15 and 127±27 pg/ml in the group pretreated 
with vehicle-1 (n=10); 84±13 and 57±26 pg/ml in the group 
pretreated with L-NAME (0.37 ?mol/animal) (n=6); 110±20
and 126±26 pg/ml in the group pretreated with L-NAME (1.11
?mol/animal) (n=12), respectively.
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Fig. 2.  Effect of 7-nitroindazole (a neuronal NOS 
inhibitor) on the centrally administered bombesin-induced 
elevation of plasma catecholamines. 7-Nitroindazole [0.03 
and 0.12 ?mol (5 and 20 ?g)/animal] or vehicle-1 (3 ?l
DMF/animal) was i.c.v. administered 30 min before the 
administration of bombesin (1 nmol/animal, i.c.v.) or 
vehicle-2 (10 ?l saline/animal, i.c.v.). (A) Increments of 
plasma catecholamines above the basal. Arrows indicate the 
administrations of 7-nitroindazole/vehicle-1 and 
bombesin/vehicle-2. (B) AUC of the bombesin-induced 
elevation of plasma catecholamines above the basal. 
*p<0.05, significantly different from vehicle-1- and 
bombesin-treated group. Other conditions were the same as 
those of Fig. 1. The actual values for noradrenaline and 
adrenaline at 0 min were 241±40 and 219±55 pg/ml in the 
group pretreated with vehicle-1 (n=11); 214±40 and 112±23
pg/ml in the group pretreated with 7-nitroindazole (0.03
?mol/animal) (n=5); 134±22 and 104±30 pg/ml in the group 
pretreated with 7-nitroindazole (0.12 ?mol/animal) (n=10), 
respectively.
Fig. 3.  Effect of S-ethylisothiourea (an inducible NOS 
inhibitor) on the centrally administered bombesin-induced 
elevation of plasma catecholamines. S-Ethylisothiourea
[2.7 and 27 nmol (0.5 and 5 ?g)/animal] or vehicle-1 (5 ?l
saline/animal) was i.c.v. administered 30 min before the 
administration of bombesin (1 nmol/animal, i.c.v.) or 
30
vehicle-2 (10 ?l saline/animal, i.c.v.). (A) Increments of 
plasma catecholamines above the basal. Arrows indicate the 
administrations of S-ethylisothiourea/vehicle-1 and 
bombesin/vehicle-2. (B) AUC of the bombesin-induced 
elevation of plasma catecholamines above the basal. The 
vehicle-1-treated groups are those of Fig. 1.
*Significantly different (p<0.05) from the vehicle-1- and 
bombesin-treated group. Other conditions were the same as 
those of Figs. 1 and 2. The actual values for 
noradrenaline and adrenaline at 0 min were 181±37 and 
84±31 pg/ml in the group pretreated with S-
ethylisothiourea (2.7 nmol/animal) (n=6); 161±21 and 90±16
pg/ml in the group pretreated with S-ethylisothiourea (27
nmol/animal) (n=11), respectively.
Fig. 4.  Effect of cycloheximide (an inhibitor of protein 
synthesis) on the centrally administered bombesin-induced 
elevation of plasma catecholamines. Cycloheximide [0.1 and 
0.2 ?mol (30 and 60 ?g)/animal] or vehicle-1 (5 ?l
saline/animal) was i.c.v. administered 120 min before the 
administration of bombesin (1 nmol/animal, i.c.v.) or 
vehicle-2 (10 ?l saline/animal, i.c.v.). (A) Increments of 
plasma catecholamines above the basal. Arrows indicate the 
administrations of cycloheximide/vehicle-1 and 
bombesin/vehicle-2. (B) AUC of the bombesin-induced 
elevation of plasma catecholamines above the basal.
*p<0.05, significantly different from vehicle-1- and 
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bombesin-treated group. Other conditions were the same as 
those of Figs. 1-3. The actual values for noradrenaline 
and adrenaline at 0 min were 105±14 and 89±18 pg/ml in the 
group pretreated with vehicle-1 (n=13); 159±32 and 129±30
pg/ml in the group pretreated with cycloheximide (0.1
?mol/animal) (n=6); 140±29 and 360±138 pg/ml in the group 
pretreated with cycloheximide (0.2 ?mol/animal) (n=13), 
respectively.
Fig. 5.  Effect of ketoprofen (a selective COX-1 
inhibitor) on the centrally administered bombesin-induced 
elevation of plasma catecholamines. Ketoprofen [1 and 2 
?mol (250 and 500 ?g)/animal] or vehicle-1 (3 ?l
DMF/animal) was i.c.v. administered 30 min before the 
administration of bombesin (1 nmol/animal, i.c.v.) or 
vehicle-2 (10 ?l saline/animal, i.c.v.). (A) Increments of 
plasma catecholamines above the basal. Arrows indicate the 
administrations of ketoprofen/vehicle-1 and 
bombesin/vehicle-2. (B) AUC of the bombesin-induced 
elevation of plasma catecholamines above the basal.
*p<0.05, significantly different from vehicle-1- and 
bombesin-treated group. The vehicle-1-treated groups are 
those of Fig. 2. Other conditions were the same as those 
of Figs. 1-4. The actual values for noradrenaline and 
adrenaline at 0 min were 219±47 and 288±60 pg/ml in the 
group pretreated with ketoprofen (1 ?mol/animal) (n=7); 
32
226±26 and 238±35 pg/ml in the group pretreated with 
ketoprofen (2 ?mol/animal) (n=11), respectively.
Fig. 6.  Effect of NS-398 (a selective COX-2 inhibitor) on 
the centrally administered bombesin-induced elevation of 
plasma catecholamines. NS-398 [0.8 and 1.6 ?mol (250 and 
500 ?g)/animal] or vehicle-1 (3 ?l DMF/animal) was i.c.v. 
administered 30 min before the administration of bombesin 
(1 nmol/animal, i.c.v.) or vehicle-2 (10 ?l saline/animal, 
i.c.v.). (A) Increments of plasma catecholamines above the 
basal. Arrows indicate the administrations of NS-
398/vehicle-1 and bombesin/vehicle-2. (B) AUC of bombesin-
induced elevation of plasma catecholamines above the basal.
*p<0.05, significantly different from vehicle-1- and 
bombesin-treated group. The vehicle-1-treated groups are 
those of Fig. 2. Other conditions were the same as those 
of Figs. 1-5. The actual values for noradrenaline and 
adrenaline at 0 min were 335±99 and 306±61 pg/ml in the 
group pretreated with NS-398 (0.8 ?mol/animal) (n=7); 
383±42 and 111±29 pg/ml in the group pretreated with NS-
398 (1.6 ?mol/animal) (n=9), respectively.
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